Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Prostatic Intraepithelial Neoplasia Clinical Trials

A listing of Prostatic Intraepithelial Neoplasia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (1) clinical trials

A Phase 2 clinical study for patients with Recurrent Glioma, Thyroid Adenoma, Colorectal Cancer, Lung Neoplasm, Uterine Corpus Cancer, Ovarian Cancer, Recurrent Thyroid Gland Carcinoma, Recurrent Breast Carcinoma, Recurrent Colon Carcinoma, Recurrent Liver Carcinoma, Pancreatic Cancer, Malignant neoplasm of kidney, Ductal Carcinoma In Situ, Recurrent Pancreatic Carcinoma, melanoma, Malignant neoplasm of prostate, bladder cancer, Advanced Malignant Solid Neoplasm, Recurrent Lymphoma, Renal Cell Carcinoma, Uterine Cancer, Endometrial Carcinoma, Malignant neoplasm of colon, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Refractory Lymphoma, Lymphoma, Breast Cancer, Cervical Cancer, Skin Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Head and Neck Carcinoma, Esophageal Carcinoma, Refractory Plasma Cell Myeloma, Recurrent Cervical Carcinoma, Multiple Myeloma, Recurrent Lung Carcinoma, Head and Neck Carcinoma, Recurrent Skin Carcinoma, Recurrent Bladder Carcinoma, Recurrent Malignant Solid Neoplasm, Rectal Cancer, Recurrent Plasma Cell Myeloma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Glioma, Recurrent Rectal Carcinoma, Cervical Intraepithelial Neoplasia, Liver and Intrahepatic Bile Duct Carcinoma, Gastric Carcinoma, Recurrent Colorectal Carcinoma, skin cancer, Refractory Malignant Solid Neoplasm

PRIMARY OBJECTIVES: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced ...